Humana (HUM) Stock Forecast & Price Target

Humana has demonstrated significant operational improvements, notably through an impressive 500 basis points margin increase in Group Medicare Advantage, attributed to favorable re-contracting efforts. The company is poised for robust revenue growth across its various segments, with management projecting enhanced earnings contributions driven by effective marketing cost moderation and advancements in care management and value-based programs. Furthermore, the continued strong performance in the CenterWell segment, along with positive guidance for Group Medicare Advantage membership growth, underscores Humana's solid positioning in the healthcare market, suggesting potential for sustained success and profitability.

Humana faces multiple downside risks that contribute to a negative outlook for its stock, including increased competition and utilization in Medicare Advantage (MA), declining MA Star ratings, and inadequate reimbursement rates, which may pressure earnings. The company's adjusted EPS estimates for 2026 and 2027 have been lowered to $9.08 and $16.24 respectively, reflecting the anticipated negative impact of a $3.5 billion headwind from MA Stars on 2026 earnings. Additionally, net investment income is projected to decline by approximately $150 million year-over-year, primarily due to reduced interest rates, further exacerbating financial pressures.